Design and Synthesis of Lipids for the Fabrication of Functional Lipidic Cubic-Phase Biomaterials
作者:Yazmin M. Osornio、Peter Uebelhart、Silvan Bosshard、Fabian Konrad、Jay S. Siegel、Ehud M. Landau
DOI:10.1021/jo301659c
日期:2012.12.7
A series of novel lipids with designed functionalities were synthesized. These lipids are based on conjugation of alpha-amino acids and their esters, cationic, anionic, neutral, and photochromic moieties to the lipophilic 9-cis octadecenyl chains by amide, ester, thioester, or amine bonds. Because of the plasticity of lipidic cubic phases, it is envisaged that when mixed with monooleoyl-rac-glycerol (monoolein, MO) and water at appropriate proportions, they would assemble to form bicontinuous lipidic cubic phases (LCPs) that exhibit the well-known material properties of LCPs such as phase stability, optical transparency, and chemical permeability. Moreover, due to the nature and position of the functionality at the headgroup region, we envision them to perform as functional materials by design.
[EN] LIPIDIC BIOMATERIALS FOR ENCAPSULATION AND TRIGGERED RELEASE<br/>[FR] BIOMATÉRIAUX LIPIDIQUES POUR L'ENCAPSULATION ET LA LIBÉRATION DÉCLENCHÉE
申请人:UNIV ZUERICH
公开号:WO2014056939A1
公开(公告)日:2014-04-17
The present invention relates to novel compounds, particularly for use as additives in a lipidic cubic phase material, and to novel lipidic cubic phase materials. These materials are biocompatible, stable and transparent and can encapsulate active compounds such as drugs and release them at will by chemical and/or photochemical triggering. A method of controlled release of a predetermined active compound, comprises the steps of: forming a lipidic cubic phase material by mixing a lipophilic component and a hydrophilic component comprising an aqueous solution containing the active compound; placing the lipidic cubic phase material in a region of interest; releasing the active compound by subjecting the lipidic cubic phase material to a chemical or photochemical stimulus.
Development of an <i>N</i>-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain
作者:Shannon N. Mostyn、Tristan Rawling、Sarasa Mohammadi、Susan Shimmon、Zachary J. Frangos、Subhodeep Sarker、Arsalan Yousuf、Irina Vetter、Renae M. Ryan、Macdonald J. Christie、Robert J. Vandenberg
DOI:10.1021/acs.jmedchem.8b01775
日期:2019.3.14
Inhibitors that target the glycinetransporter2, GlyT2, show promise as analgesics, but may be limited by their toxicity through complete or irreversible binding. Acyl-glycine inhibitors, however, are selective for GlyT2 and have been shown to provide analgesia in animal models of pain with minimal side effects, but are comparatively weak GlyT2 inhibitors. Here, we modify the simple acyl-glycine by
靶向甘氨酸转运蛋白 2、GlyT2 的抑制剂显示出作为镇痛剂的前景,但可能会通过完全或不可逆的结合而受到毒性的限制。然而,酰基甘氨酸抑制剂对 GlyT2 具有选择性,并且已被证明可在动物疼痛模型中提供镇痛作用,且副作用最小,但 GlyT2 抑制剂的作用相对较弱。在这里,我们通过合成具有一系列 l 和 d 构型的氨基酸头基的脂质类似物来修饰简单的酰基甘氨酸,以产生纳摩尔亲和力的选择性 GlyT2 抑制剂。强效抑制剂油酰-d-赖氨酸 (33) 对人和大鼠血浆和肝微粒体的降解也具有抗性,并且在大鼠腹腔注射后迅速吸收并容易穿过血脑屏障。